Associated Genetic Biomarkers
Hepatic leukemia factor (HLF) is a gene that encodes a protein that functions as a transcriptional activator. Fusions, missense mutations, silent mutations are observed in cancers such as intestinal cancer and ovarian cancer.
HLF is altered in 0.10% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial serous adenocarcinoma, and esophageal adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in HLF are HLF A254T (0.22%), HLF E2Q (0.39%), HLF M86I (0.22%), HLF R275S (0.39%), and HLF R6Q (0.22%) .
HLF status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain HLF status as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
The most frequent alteration to serve as an inclusion eligibility criterion is TCF3-HLF Fusion .
Significance of HLF in Diseases
B-Cell Acute Lymphoblastic Leukemia +
HLF is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain HLF status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.